BUSINESS BRIEF
Project Aura is a leading fertility and reproductive healthcare centre based in Southern India. Positioned as a trusted partner for individuals and couples seeking parenthood, the centre addresses fertility challenges arising from modern urban lifestyles through clinically advanced and patient-centric care.
Key Highlights:
- The facility is equipped to accommodate 3–4 in-patient beds and features a Laminar Airflow Operation Theatre, critical for maintaining sterile conditions during fertility procedures.
- Clinical leadership is anchored by a highly experienced lead doctor with an 80–85% surgical success rate and a 90–95% conversion rate from consultations to treatment initiation.
- Average revenue per treatment cycle is INR 3.0–3.5 Lakhs, with the centre currently operating at an average of 6 cycles per month, scaling to 9 cycles in the most recent month.
- The business benefits from repeat patient engagement, with an average of 2 cycles per patient, each cycle typically spanning 2–3 months, providing strong revenue visibility and continuity.
- The centre currently generates approximately INR 30 Lakhs in monthly revenue, with a clear growth plan to scale to ~INR 50 Lakhs
per month.
NOTE: FY2026 Revenue: INR 3 Cr, EBITDA: INR 0.66 Cr
Products & Services
- Intrauterine Insemination (IUI)
- In-Vitro Fertilisation (IVF)
- Intracytoplasmic Sperm Injection (ICSI-ET)
- Laparoscopy & Hysteroscopy
- Fertility Diagnosis & Treatment
- Ultrasound Imaging
- Hormonal Profiling
- Andrology Laboratory
- Embryology Laboratory
- In-house Pharmacy
Proposal
Industry
Hospitals and Healthcare
Sub Industry
Hospitals and Extended Care & IVF
Nature of Business
B2C
Sector
Services
Region
Asia
Open For Dilution
26 %
Top Customer
Ask
INR 2 Cr
End use of fund
- Patient acquisition & marketing
- Brand partnerships
- Community outreach
- Expansion of the fertility centre network
- Operational scaling
Business Operation Information
Financial Information |
2025 (in INR Cr) | 2024 (in INR Cr) | 2023 (in INR Cr) |
|---|---|---|---|
Sales |
2.00 | . | . |
EBITDA |
|||
PAT |